Hypoxia Imaging for Esophageal Cancer to Guide Personalized Radiation Therapy

Phase 1, open-label, single-arm trial, sponsored by University of Utah. Primary endpoints: Rate of grade >= 4 esophageal adverse events attributed to radiation therapy within 30 days, Rate of grade >= 4 esophageal adverse events attributed to radiation therapy within 84 days and 1 more. Started Oct 2021; status: recruiting.